Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.05 GBX | -.--% | -14.58% | -69.40% |
May. 28 | NetScientific backs Wanda; Inspirit Energy wins deal | AN |
May. 10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 24.13M 30.75M | Sales 2025 * | 71.12M 90.61M | Capitalization | 16.03M 20.43M |
---|---|---|---|---|---|
Net income 2024 * | -18M -22.93M | Net income 2025 * | 3M 3.82M | EV / Sales 2024 * | 1.61 x |
Net Debt 2024 * | 22.86M 29.12M | Net Debt 2025 * | 20.43M 26.03M | EV / Sales 2025 * | 0.51 x |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
4.7
x | Employees | 27 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.82% |
Latest transcript on Shield Therapeutics plc
1 week | -14.58% | ||
1 month | +51.85% | ||
3 months | -10.87% | ||
6 months | -66.12% | ||
Current year | -69.40% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18-07-25 | |
Director/Board Member | 66 | 16-01-31 | |
Director/Board Member | 57 | 21-05-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.05 | -.--% | 668,370 |
24-05-30 | 2.05 | -4.65% | 1,079,687 |
24-05-29 | 2.15 | -8.51% | 3,415,207 |
24-05-28 | 2.35 | -2.08% | 5,084,763 |
24-05-24 | 2.4 | -.--% | 3,366,745 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-69.40% | 20.4M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- STX Stock